Jd. Brioni et al., ANXIOLYTIC-LIKE EFFECTS OF THE NOVEL CHOLINERGIC CHANNEL ACTIVATOR ABT-418, The Journal of pharmacology and experimental therapeutics, 271(1), 1994, pp. 353-361
The hydrochloride salt of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) iso
xazole (ABT-418), a potent activator of select subtypes of neuronal ni
cotinic acetylcholine receptors enhanced retention in memory tests and
induced anxiolytic-like effects in mice in the elevated plus maze. In
the present studies in rat, ABT-418 induced a significant increase in
the time spent by the rats in the open arms of the elevated plus maze
(0.62 mu mol/kg i.p.); the effect persisted up to 60 min after the in
jection and was blocked by mecamylamine (15 mu mol/kg), a centrally ac
ting nicotinic acetylcholine receptor channel blocker. ABT-418 was and
fold and 1.6-fold more potent than diazepam and ondansetron, respecti
vely. The anxiolytic-like effect of ABT-418 was observed after oral ad
ministration in rats (10-30 mu mol/kg) and at slightly higher doses in
20-month-old rats (1.9 mu mol/kg i.p.). Major metabolites of ABT-418
-methyl-5-(3-methyl-5-isoxazolyl)-2-pyrrolidinone, cis-ABT-418 N-oxide
and trans-ABT-418 N-oxide] were inactive in the plus maze in mice up
to 6.2 mu mol/kg, did not affect body temperature and had minimal effe
cts on locomotion. Like (-)-nicotine, ABT-418 was effective (4 and 13
mu mol kg(-1) day(-1)) to induce anxiolytic-like effects after a 14-da
y treatment through minipumps implanted subcutaneously. Acute administ
ration of ABT-418 (0.62 mu mol/kg i.p.) also attenuated the anxiogenic
-like effect elicited by withdrawal from chronic (-)-nicotine treatmen
t. ABT-418 (0.62 and 1.9 mu mol/kg i.p.) did not impair spatial memory
in the water maze and did not potentiate the amnestic effects of diaz
epam (7.0 mu mol/kg i.p.) in this test. These data demonstrate that AB
T-418 exhibits anxiolytic-like properties in rodents independently of
the route of administration of the compound and that it may represent
a novel therapeutic approach for the treatment of emotional disorders
that have anxiety as a major behavioral manifestation.